modelA06AX06
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Tegaserod | |
| ATC code: | A06AX06 | route: | oral |
| compartments: | 1 | |
| dosage: | 6 | mg |
| volume of distribution: | 87.1 | L |
| clearance: | 1370 | mL/min |
| other parameters in model implementation | ||
Tegaserod is a selective serotonin 5-HT4 receptor partial agonist used for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation in women under the age of 65. It was withdrawn from the market in many countries due to cardiovascular safety concerns but has since been reintroduced with restricted indication in some regions.
Pharmacokinetics
Pharmacokinetic parameters observed in healthy male and female adults following oral administration.
References
Hamatani, T, et al., & Fujio, Y (2020). Thorough QT/QTc Study Shows That a Novel 5-HT. Clinical pharmacology in drug development 9(8) 938–951. DOI:10.1002/cpdd.778 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32087003
Appel, S, et al., & Duvauchelle, T (1997). First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist. Journal of clinical pharmacology 37(3) 229–237. DOI:10.1002/j.1552-4604.1997.tb04785.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/9089425
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)